Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.

Date publication

février 2020

Journal

The lancet. Gastroenterology & hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric

Tous les auteurs :
Rullier E, Vendrely V, Asselineau J, Rouanet P, Tuech JJ, Valverde A, de Chaisemartin C, Rivoire M, Trilling B, Jafari M, Portier G, Meunier B, Sieleznieff I, Bertrand M, Marchal F, Dubois A, Pocard M, Rullier A, Smith D, Frulio N, Frison E, Denost Q

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32043980

Résumé

GRECCAR 2 was the first multicentre, randomised trial to compare local excision with total mesorectal excision in downstaged low rectal cancer. Encouraging oncological results were noted at 3 years' follow-up but needed to be corroborated with longer follow-up. In this study, we aimed to report the 5-year oncological outcomes, including local recurrence, metastatic disease, and survival.

Référence

Lancet Gastroenterol Hepatol. 2020 Feb 7;: